1. Home
  2. OCGN

as of 02-19-2026 1:13pm EST

$1.56
+$0.08
+5.41%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Founded: 2013 Country:
US
Employees: N/A City: MALVERN
Market Cap: 387.3M IPO Year: 2014
Target Price: $7.00 AVG Volume (30 days): 3.8M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.09 EPS Growth: 31.58
52 Week Low/High: $0.52 - $1.96 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: -100.00%
Revenue Growth (this year): 35.88% Revenue Growth (next year): -42.98%
P/E Ratio: N/A Index: N/A
Free Cash Flow: -45527000.0 FCF Growth: N/A

AI-Powered OCGN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 19 hours ago

AI Recommendation

hold
Model Accuracy: 66.67%
66.67%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Ocugen Inc. News

OCGN Breaking Stock News: Dive into OCGN Ticker-Specific Updates for Smart Investing

All OCGN News

Share on Social Networks: